49 results on '"Benedict, Agnes"'
Search Results
2. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
3. A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective
4. Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
5. A cost‐effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first‐line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan
6. P857: COMPARISON OF MULTIPLE MYELOMA TREATMENT PATTERNS IN 2022 ACROSS UNITED STATES, SOUTH AMERICA, EUROPE AND ASIA
7. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
8. Simulation and Matching-Based Approaches for Indirect Comparison of Treatments
9. Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges
10. Overview of Parametric Survival Analysis for Health-Economic Applications
11. 219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients
12. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
13. Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer - a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
14. TOTAL COST IN THE 1ST YEAR FOLLOWING DIAGNOSIS OF PROSTATE CANCER: ESTIMATES FROM US SEER-MEDICARE DATA: 168
15. Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
16. Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma
17. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost–effectiveness analysis
18. Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.
19. Economic Evaluation of Carfilzomib+Dexamethasone (Kd) Vs Bortezomib+Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (R/RMM)
20. Economic evaluation of carfilzomib + lenalidomide + dexamethasone (KRd) vs. lenalidomide + dexamethasone (Rd) in relapsed or refractory multiple myeloma (R/RMM).
21. Indirect Comparison to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Bortezomib + Thalidomide + Dexamethasone: A Matching Adjusted Indirect Comparison
22. Indirect Comparisons to Assess the Relative Efficacy of Carfilzomib + Lenalidomide + Dexamethasone Versus Panobinostat + Bortezomib + Dexamethasone and Bortezomib + Dexamethasone: A Matching Adjusted Indirect Comparison
23. Overall survival information and population correspondence for FDA cancer accelerated approval indications between 2006 and 2021.
24. Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States
25. Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – a Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
26. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population
27. Modelling survival in hepatocellular carcinoma
28. Retrospective claims analysis of palliative care costs and survival in a U.S. metastatic renal cell (mRCC) population.
29. Potential economic impact of increasing low dose aspirin usage on CVD in the US
30. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia
31. Violence in the Classroom.
32. SUNBEAMS.
33. Farm Children.
34. Children at the Cross Roads
35. Play Centers for School Children: A Guide to Their Establishment and Operation.
36. Your Best Friends Are Your Children
37. Book Review: Social Work Book-of-the-Month: Parents and Children Go to School
38. The Happy Home: A Guide to Family Living
39. Children at the Crossroads
40. The Elements of Education.
41. Security and Stimulation.
42. Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell population.
43. Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
44. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
45. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
46. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK.
47. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
48. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
49. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.